BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27528549)

  • 1. Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.
    Cejka D; Parada-Rodriguez D; Pichler S; Marculescu R; Kramer I; Kneissel M; Gross T; Reisinger A; Pahr D; Monier-Faugere MC; Haas M; Malluche HH
    Kidney Int; 2016 Oct; 90(4):828-34. PubMed ID: 27528549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
    Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
    Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sclerostin deficiency modifies the development of CKD-MBD in mice.
    Kaesler N; Verhulst A; De Maré A; Deck A; Behets GJ; Hyusein A; Evenepoel P; Floege J; Marx N; Babler A; Kramer I; Kneissel M; Kramann R; Weis D; D'Haese PC; Brandenburg VM
    Bone; 2018 Feb; 107():115-123. PubMed ID: 29175269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF-23 and sclerostin in serum and bone of CKD patients.
    Lima F; Monier-Faugere MC; Mawad H; David V; Malluche HH
    Clin Nephrol; 2023 May; 99(5):209-218. PubMed ID: 36970967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Gsα in osteocytes leads to osteopenia due to sclerostin induced suppression of osteoblast activity.
    Fulzele K; Dedic C; Lai F; Bouxsein M; Lotinun S; Baron R; Divieti Pajevic P
    Bone; 2018 Dec; 117():138-148. PubMed ID: 30266511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Matrix Composition Following PTH Treatment is Not Dependent on Sclerostin Status.
    Ross RD; Mashiatulla M; Robling AG; Miller LM; Sumner DR
    Calcif Tissue Int; 2016 Feb; 98(2):149-57. PubMed ID: 26514840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
    Alzahrani MM; Rauch F; Hamdy RC
    Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet.
    Zaloszyc A; Choquet P; Sayeh A; Bartosova M; Schaefer B; Huegel U; Aubertin-Kirch G; Healy C; Severac F; Rizzo S; Boivin G; Schaefer F; Fischbach M; Bacchetta J; Bahram S; Schmitt CP
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TGF-β in a mouse model of high turnover renal osteodystrophy.
    Liu S; Song W; Boulanger JH; Tang W; Sabbagh Y; Kelley B; Gotschall R; Ryan S; Phillips L; Malley K; Cao X; Xia TH; Zhen G; Cao X; Ling H; Dechow PC; Bellido TM; Ledbetter SR; Schiavi SC
    J Bone Miner Res; 2014; 29(5):1141-57. PubMed ID: 24166835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin and Dickkopf-1 in renal osteodystrophy.
    Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted postnatal knockout of Sclerostin using a bone-targeted adeno-associated viral vector increases bone anabolism and decreases canalicular density.
    O'Donohue AK; Xiao Y; Lee LR; Schofield T; Cheng TL; Munns CF; Baldock PA; Schindeler A
    Bone; 2023 Feb; 167():116636. PubMed ID: 36462771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease.
    Lau WL; Linnes M; Chu EY; Foster BL; Bartley BA; Somerman MJ; Giachelli CM
    Nephrol Dial Transplant; 2013 Jan; 28(1):62-9. PubMed ID: 23045434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoblast function and bone histomorphometry in a murine model of Rett syndrome.
    Blue ME; Boskey AL; Doty SB; Fedarko NS; Hossain MA; Shapiro JR
    Bone; 2015 Jul; 76():23-30. PubMed ID: 25769649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.
    Masci M; Wang M; Imbert L; Barnes AM; Spevak L; Lukashova L; Huang Y; Ma Y; Marini JC; Jacobsen CM; Warman ML; Boskey AL
    Bone; 2016 Jun; 87():120-9. PubMed ID: 27083399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Long-Term Sclerostin Deficiency on Trabecular Bone Mass and Adaption to Limb Loading Differ in Male and Female Mice.
    Albiol L; Büttner A; Pflanz D; Mikolajewicz N; Birkhold AI; Kramer I; Kneissel M; Duda GN; Checa S; Willie BM
    Calcif Tissue Int; 2020 Apr; 106(4):415-430. PubMed ID: 31873756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover.
    Huybrechts Y; Evenepoel P; Haarhaus M; Cavalier E; Dams G; Van Hul W; D'Haese PC; Verhulst A
    Nutrients; 2023 Jan; 15(3):. PubMed ID: 36771305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
    Fang Y; Ginsberg C; Seifert M; Agapova O; Sugatani T; Register TC; Freedman BI; Monier-Faugere MC; Malluche H; Hruska KA
    J Am Soc Nephrol; 2014 Aug; 25(8):1760-73. PubMed ID: 24578135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.